The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors

R Condiotti, S Slavin, V Barak, A Nagler - Leukemia research, 1996 - Elsevier
Donor-derived cell-mediated immunotherapy has been shown to be an effective tool for
reinduction of remission in chronic myeloid leukemia (CML) patients who have relapsed …
被引用次数：11 相关文章

The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and pha-stimulated T cell proliferation from normal donors

R Condiotti, S Slavin, V Barak, A Nagler - Leukemia Research, 1996 - elibrary.ru
Donor-derived cell-mediated immunotherapy has been shown to be an effective tool for
reinduction of remission in chronic myeloid leukemia (CML) patients who have relapsed …

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors

R Condiotti, S Slavin, V Barak… - Leukemia …, 1996 - pubmed.ncbi.nlm.nih.gov
Donor-derived cell-mediated immunotherapy has been shown to be an effective tool for
reinduction of remission in chronic myeloid leukaemia (CML) patients who have relapsed …

[引用][C] The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal …

R CONDIOTTI, S SLAVIN, V BARAK… - Leukemia …, 1996 - pascal-francis.inist.fr
The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer
(NK) cell and PHA-stimulated T cell proliferation from normal donors CNRS Inist Pascal-Francis …

The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and pha-stimulated T cell proliferation from normal donors

R Condiotti, S Slavin, V Barak, A Nagler - Leukemia Research, 1996 - infona.pl
Donor-derived cell-mediated immunotherapy has been shown to be an effective tool for
reinduction of remission in chronic myeloid leukemia (CML) patients who have relapsed …

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.

R Condiotti, S Slavin, V Barak, A Nagler - Leukemia Research, 1996 - europepmc.org
Donor-derived cell-mediated immunotherapy has been shown to be an effective tool for
reinduction of remission in chronic myeloid leukaemia (CML) patients who have relapsed …